Papers by Christopher Marchand
aan.mmsh.univ-aix.fr
... BOUCH.~~A (A.), 1984. -Politique des barrnges et de~seloppement agricole au Maroc. ... (S.), ... more ... BOUCH.~~A (A.), 1984. -Politique des barrnges et de~seloppement agricole au Maroc. ... (S.), 1995. - Rénovation du systbme hydraulique de l'oasis de Gafsa; restnidu-ration ou altération? ... CHERIF (A.), KASS.~ (A.), 1995. - L'Eau et l'agriculture irrigu& en îùnisie, Public. Fac. ...
Journal Français d'Ophtalmologie, 2013
Resume Nous rapportons le cas d’un patient ayant presente une occlusion de la veine centrale de l... more Resume Nous rapportons le cas d’un patient ayant presente une occlusion de la veine centrale de la retine associee a l’apparition de blanc periveinulaire. La prise en charge par OCT spectral domain en mode « en-face » a permis une mise en evidence precise de ces zones de micro-infarcissement. Ce cas clinique souligne l’utilite du mode « en-face » dans le cadre de la surveillance des OVCR
Frontiers in Oncology, 2021
Purpose The aim of this study was to characterize chondrosarcoma tumor infiltration by immune cel... more Purpose The aim of this study was to characterize chondrosarcoma tumor infiltration by immune cells and the expression of immunologically relevant molecules. This information may contribute to our understanding of the role of immunological events in the pathogenesis of chondrosarcoma and to the rational design of immunotherapeutic strategies. Patients and Methods A tissue microarray (TMA) containing 52 conventional and 24 dedifferentiated chondrosarcoma specimens was analyzed by immunohistochemical staining for the expression of parameters associated with tumor antigen-specific immune responses, namely, CD4+ and CD8+ tumor infiltrating lymphocytes (TILs) and the expression of HLA class I heavy chain, beta-2 microglobulin (β2m), HLA class II and immune checkpoint molecules, B7-H3 and PD-1/PD-L1. The results were correlated with histopathological characteristics and the clinical course of the disease. Results CD8+ TILs were present in 21% of the conventional and 90% of the dedifferent...
Journal of the American College of Surgeons, 2019
Oncotarget, Jan 5, 2017
Pancreatic ductal adenocarcinoma (PDAC) has one of the poorest prognosis among malignancies. Thus... more Pancreatic ductal adenocarcinoma (PDAC) has one of the poorest prognosis among malignancies. Thus, the identification of markers useful in developing innovative diagnostic and therapeutic methods is an imperative need. Folate receptor alpha (FRα) has been associated with prognosis in several cancers and has served as a target of novel anti-tumor therapies. However, FRα expression in PDAC and its correlation with the clinical course of the disease has not been thoroughly investigated. In this study, we analyzed FRα expression in 140 PDAC specimens and 7 PDAC cell lines in order to define the significance of FRα expression in PDAC and its potential role as a target for immunotherapy. Immunohistochemical analysis demonstrated that FRα expression intensity was low, intermediate and high in 22(16%), 73(52%) and 45(32%) PDACs, respectively. The staining was located in both membrane and cytoplasm in most cases (123, 88%). Lower FRα expression was associated with cigarette smoking (p<0.0...
Oncotarget, Jan 8, 2016
Cancer stem cells (CSC) typically over-express aldehyde dehydrogenase (ALDH). Thus, ALDHbright tu... more Cancer stem cells (CSC) typically over-express aldehyde dehydrogenase (ALDH). Thus, ALDHbright tumor cells represent targets for developing novel cancer prevention/treatment interventions. Loss of p53 function is a common genetic event during cancer development wherein small molecular weight compounds (SMWC) that restore p53 function and reverse tumor growth have been identified. Here, we focused on two widely studied p53 SMWC, CP-31398 and PRIMA-1, to target ALDHbright CSC in human breast, endometrial and pancreas carcinoma cell lines expressing mutant or wild type (WT) p53. CP-31398 and PRIMA-1 significantly reduced CSC content and sphere formation by these cell lines in vitro. In addition, these agents were more effective in vitro against CSC compared to cisplatin and gemcitabine, two often-used chemotherapeutic agents. We also tested a combinatorial treatment in methylcholantrene (MCA)-treated mice consisting of p53 SMWC and p53-based vaccines. Yet using survival end-point analy...
The spine journal : official journal of the North American Spine Society, Jun 9, 2015
There are currently no generally accepted biomarkers utilized in the clinical treatment of chordo... more There are currently no generally accepted biomarkers utilized in the clinical treatment of chordoma tumors. CSPG4 has been associated with disease severity in other tumors. To characterize the frequency of CSPG4 expression in chordoma tumors and to correlate it with disease severity and clinical outcome. Retrospective review of clinical outcomes and immunohistochemical staining using tissue micro-array. Eighty-six patients treated for chordoma at a single center (1985-2007). Survival and incidence of metastases. Pathologic specimens of chordoma tumors were evaluated for the expression of CSPG4 by immunohistochemical staining with mAbs. Chi-square testing and Cox proprotional hazard regression analysis were used to evaluate the impact of CSPG4 expression on survival and incidence of metastases, while controlling for patient age, sex and surgical margins. Average patient age at the time of presentation was 59.8 years (SD 13.7). Average follow-up was 6.5 years (SD 4.8). Twenty (23%) pa...
The Journal of Immunology, Apr 1, 2009
Molecular oncology, Jan 30, 2015
This review discusses the potential use of intracellular tumor antigens as targets of antibody-ba... more This review discusses the potential use of intracellular tumor antigens as targets of antibody-based immunotherapy for the treatment of solid tumors. In addition, it describes the characteristics of the intracellular tumor antigens targeted with antibodies which have been described in the literature and have been identified in the authors' laboratory. Finally, the mechanism underlying the trafficking of the intracellular tumor antigens to the plasma membrane of tumor cells are reviewed.
Cancer Research, 2015
Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA Allogeneic leuke... more Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA Allogeneic leukemia and cancer epithelial (CE) cells have been recently shown to induce,in vitro, NK cell abnormalities (NKCA). The latter include NK cell depletion and apoptosis as well as natural cytotoxic receptor (NCR) CD16 down-regulation. The potential negative impact of leukemia and CE cell induced NKCAs on the in vivo anti-tumor activity of NK cells and the limited information about strategies to protect NK cells from NKCAs have prompted us to characterize NKCAs and to develop strategies to counteract them. NKCA induction by leukemia and CE cells is influenced neither by interleukin-2 (IL-2) treatment nor by HLA class I antigen expression, but is abrogated by a long term culture of peripheral blood mononuclear cells (PBMCs) at 37 oC. Following a 10 day culture of PBMCs, NK cells become resistant to cancer cell induced NKCA but maintain their cytotoxic activity. Actinomycin D restores the susceptibility of long term NK (LTNK) cells to NKCAs suggesting that the generation of resistance to NKCAs requires RNA transcription. TAPI-0, a functional analogue of the tissue inhibitor of metalloproteinases (TIMP) 3, inhibits cancer cell induced NKCAs indicating a role for a restricted number of metalloproteinases (MMPs) in the generation of this phenomenon. This conclusion is supported by the reduced susceptibility to cancer cell induced NKCAs of LTNK cells in which TIMP3 gene and protein are over-expressed. Finally, subcutaneous infusion of IL-2 stimulated LTNK cells inhibited subcutaneous growth of the monoblastic leukemia cells, ML-2 in CB17scid mice while short term, IL-2 stimulated NK cells did not suggesting that LTNK cells have significant anti-leukemia capacity in vivo. This information may contribute to the rational design of targeted strategies to enhance the efficacy of NK cell-based-immunotherapy for the treatment of myeloid leukemias with haploidentical or allogeneic NK cells. Citation Format: Giuseppe Sconocchia, Roberto Arriga, Sara Caratelli, Giulia Lanzilli, Andrea Coppola, Giulio C. Spagnoli, Adriano Venditti, Sergio Amadori, Davide Lauro, Maria I. Del Principe, Luca Maurillo, Francesco Buccisano, Barbara Capuani, Xinhui Wang, Soldano Ferrone. Association of long term NK cell culture and TIMP3 over-expression with NK cell reduced susceptibility to leukemia and epithelial cancer cell induced damage. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4050. doi:10.1158/1538-7445.AM2015-4050
Journal of the American College of Surgeons, 2012
Journal of Immunotherapy, 2009
Ability to cross-present exogenous antigens in the human leukocyte antigen class I pathway is key... more Ability to cross-present exogenous antigens in the human leukocyte antigen class I pathway is key to the antigen presenting function of mature tumor cell-loaded dendritic cells (DC). Conditions of DC maturation have been shown to be important for DCs ability to produce proinflammatory cytokines and induce T cell effector functions. However, it remains unknown if the different pathways of maturation are associated with modulation of the ability of mature DCs to crosspresent tumor antigens (TA). Here, we compare DC matured with 3 clinically relevant cytokine combinations including interleukin (IL)-1β, tumor necrosis factor-α, IL-6 (termed DC-0), DC-0 cells incubated with prostaglandin-2 (termed DC-0+prostaglandin-2), or DC treated with interferon-γ, interferon-α, tumor necrosis factor-α, Poly I:C, and IL1-β (termed DC-1). We found that these DC vary in their ability to cross-present TA to cytotoxic T lymphocytes (CTL), with the DC-1 cytokine combination being significantly more effective than the other 2. TA cross presentation and CTL priming were strongly correlated with level of expression of the antigen processing machinery components, TAP1 and TAP2, indicating that these components could be used as biomarkers to standardize DC preparations for optimal function. However, the upregulation of TAP1/TAP2 was not sufficient to explain the enhanced cross-presentation ability of DC-1 cells, as the use of IFN-γ alone to up-regulate TAP1/TAP2 did not generate DC as effective at cross-presentation as the full DC-1 maturation cytokine combination. These data indicate for the first time that the pathways of DC maturation modulate antigen processing machinery component expression to different extents and that differently matured DC vary in the ability to cross-present TA to human leukocyte antigen class I-restricted CTL.
International Archives of Allergy and Immunology, 2003
Immunologic Research, 2011
PLX4032 is a BRAF-selective inhibitor shown to be efficacious in the treatment of melanomas prese... more PLX4032 is a BRAF-selective inhibitor shown to be efficacious in the treatment of melanomas presenting with the BRAF V600E mutation. However, favorable responses to treatment are short-lived, and complete remission is rarely observed. Therefore, it is important to identify novel therapies designed to enhance treatment responses and to increase the longevity of initial response to BRAF inhibitors. To this end, we characterized the effects of the 225.28 chondroitin sulfate proteoglycan 4 (CSPG4)-specific monoclonal antibody (mAb) capable of blocking multiple signaling pathways important to cell growth, migration, and survival. Addition of 225.28 to the treatment regimen enhanced the in vitro response magnitude and the duration efficacy of PLX4032 in treating CSPG4 ? , BRAF V600E melanoma cells (melanoma BRAF(V600E)/CSPG4? cells). Data presented in this report demonstrated that (1) treatments comprised of PLX4032 and mAb 225.28 were more effective at inhibiting melanoma BRAF(V600E)/CSPG4? cell growth than either agent alone, (2) mAb 225.28 prevented/delayed the development of resistance in melanoma BRAF(V600E)/CSPG4? cells to PLX4032, and (3) the mechanism of action of the combination therapy caused a down-regulation in multiple signaling pathways. This study provides a foundation for future investigations designed to improve BRAF inhibitor effectiveness in vitro and in vivo for treating melanoma BRAF(V600E)/CSPG4? cells in combination with a CSPG4-specific mAb.
Uploads
Papers by Christopher Marchand